Ceclor
(Cefaclor)ApprovedSmall molecule
Eli LillyCeclor is one of 28 small molecule programs targeting Endocarditis. It is currently in Approved.
2
Indications
1
Total Trials
1
Active Trials
27
Competitors
3
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
40 competitors in Endocarditis
#DrugCompanyPhaseTrials
1Zyvox
PfizerApproved
Cubicin
BBaxter Healthcare Corporation
Approved
Amoxil
GGlobal Antibiotics Research and Development Partnership
Approved
Gantanol
CConrado Roberto Hoffmann Filho
Approved
Rocephin
CConrado Roberto Hoffmann Filho
Approved
Rifadin
SanofiPhase 3
Pathocil
WWyeth-Lederle Vaccines
Approved
Levaquin
WWim Janssens
Phase 3
Ceclor
Eli LillyApproved
Rifampicin
Boehringer IngelheimPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Regulatory
FDA Approval Timeline[4]
Jan 1, 1982
CECLOR
NDA NDA050521
Jan 1, 1982
CECLOR
NDA NDA050522
Jun 28, 1996
CECLOR CD
NDA NDA050673
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Cefaclor. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]